ROLE OF NEUROSPECIFIC PROTEINS IN THE DEVELOPMENT OF COGNITIVE DYSFUNCTION IN PATIENTS WITH TYPE 1 DIABETES

Type 1 (type 1 DM) diabetes mellitus is one of the common chronic metabolic diseases, which currently is a significant problem due to disability at a young age and reduce life expectancy. Despite the fact that type 1 diabetes accounts for only 10% of all patients with diabetes, it occurs particularly hard, with a tendency to progression. One of the targets of type 1 diabetes is the central nervous system with the further formation of cognitive dysfunction in young age leads to diminished quality of life. Cognitive deficits may be the result not only of structural lesions of the brain, but it may be due to the development of metabolic disorders. In the case of timely diagnosis and treatment of cognitive impairment associated with metabolic changes that can partially or completely regress. The aim of this study was to identify biomarkers of the brain damage in young patients with type 1 diabetes. The study involved 58 patients with  type  1  diabetes,  the  control  group  comprised  29  healthy  controls.  The  complex  included a neuropsychological examination which was used for testing the Montreal scale (MoCA test) rapid screening of cognitive impairment, assessment of quality of life using a common questionnaire Medical Outcomes Study Short Form (MOS SF-36) and the specific audit – dependent quality of life (ADDQoL). To evaluateearly markersin the developmentof cognitive dysfunctionwere identifiedneurospecific proteins – S100 protein and glial fibrillary acidic protein (GFAP), myelin basic protein (MBP). Found an increased level of neurospecific protein that was correlated with parameters of carbohydrate metabolism, poor quality of life and severe cognitive deficiency (MoCA test lower than 26 points).

type 1 diabetes mellitus, neurospecific proteins, quality of life, cognitive dysfunction

1. IDF Diabetes Atlas. 2013 http://www.idf.org/diabetesatlas (Acessed: 09 October 2013)

2. Suncov Yu.I., Bolotskaya L.L., Maslova O.V., Kazakov I.V. Diabetes mellitus, 2011, no. 1, pp. 15–18 (in Russian).

3. Shishkova Yu.A., Motovilin O.G., Divisenko S.I., Surko va Ye.V., Mayorov A.Yu. Diabetes mellitus, 2010, no. 4, pp. 43–47 (in Russian).

4. Starostina Ye.G. Biomedical and psychosocial aspects of diabetes and obesity: the physician-patient interaction and ways to optimize. Author. dis. Dr. med. sci. Moscow, 2003. 44 p. (in Russian).

5. Jacobsonde A.M., Groot M., Samson J.A. The evaluation of two measures of quality of life in patients with type I and type II diabetes. Diabetes Care, 1994, vol. 17, no. 4, pp. 267–274.

6. Klein B.E., Klein R., Moss S.E. Self-rated health and diabetes of longduration. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care, 1998, vol. 21, pp. 236–240.

7. Trief P.M., Wade M.J., Pine D., Weinstock R.S. A comparison of health-related quality oflife of elderly and younger insulin-treated adults with diabetes. Age and Ageing, 2003, vol. 32, pp. 613–618.

8. Samoilova Yu.G., Oleinik O.A. Pediatric, 2010, vol. 89, no. 5, pp. 57–63 (in Russian).

9. Craft S. The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia. Arch. Neurol., 2009, vol. 66, pp. 300–305.

10. Kalaria R.N. Diabetes, microvascular pathology and Alzheimer disease. Nature Rev. Neurology, 2009, vol. 5, pp. 305–306.

11. Cox D.J., Kovatchev B.P., Gonder-Frederick L.A. Relationships between hyperglycemia and cognitive performance among adults with type 1 and type 2 diabetes. Diabetes Care, 2005, vol. 28, pp. 71–77.

12. Ineke Brands. Diabetes and the brain: Cognitive performance in type 1 and type 2 diabetes mellitus. N., Gildeprint Drukkerijen B.V., 2007. P. 223.

13. Ryan C.M., Geckle M.O., Orchard T.J. Cognitive efficiency declines over time in adults with Type 1 diabetes: effects of micro and macrovascular complications. Diabetologia, 2003, vol. 46, pp. 940–94.

14. Novik A.A., Ionova T.I. Guidelines for quality of life research in medicine. Moscow, OLMA Media Grupp Publ., 2007. 320 p. (in Russian).

15. ADDQoL, License от Prof. Clare Bradley: 24.2.94. Russian for Russia 12.8.10 (from Standard UK English rev. 1.3.06) Health Psychology Research, Dept of Psychology, Royal Holloway, University of London, Egham, Surrey, TW20 0EX, UK for Dr. Mariia Novoselova, Siberian State Medical University, ref. HPR 1153.

16. Nasreddine Z.S., Phillips N.A., Bédirian V., Charbonneau S., Whitehead V., Collin I., Cummings J.L., Chertkow H. The Montreal Cognitive Assessment (MoCA©): A Brief Screening Tool For Mild Cognitive Impairment. J. Am. Geriatr. Soc., 2005, vol. 53, pp. 695–699.

17. Sinclair A.J., Girling A.J., Bayer A.J. Cognitive dysfunction in older subjects with diabetes mellitus: impact on diabetes self-management and use of care services. All Wales Research into Elderly (AWARE) Study. Diabetes Research and Clinical Practice, 2000, vol. 50, pp. 203–212.

18. Zakharov V.V. Consilium medicum, vol. 13, no. 2, pp. 82–90 (in Russian).

19. Grishanova T.G., Budaev A.V., Grigor'ev E.V. Medical emergency conditions, 2011, pp. 32–33 (in Russian).

20. Zimmer D.B., Weber D.J. The Calcium-Dependent Interaction of S100B with Its Protein Targets. Cardiovascular Psychiatry and Neurology, 2010, vol. 2010, pp. 1–18.

21. Pavlov K.A., Gurina O.I., Dmitrieva T.B., Makarov A.V., Chekhonin V.P. Bulletin of Experimental Biology and Medicine, 2008, no. 11, pp. 535–539 (in Russian).

22. Li Jing, Qingping He, Jian-Zhong Zhang, Andy LiP. Temporal Profile of Astrocytes and Changes of OligodendrocyteBased Myelin Following Middle Cerebral Artery Occlusion in Diabetic and Non-diabetic Rats. Int. J. Biol. Sci., 2013, vol. 9, no. 2, pp. 190–199.

23. Pesaresi M., Giatti S., Calabrese D., Maschi O., Caruso D., Melcangi R.C. Dihydroprogesterone increases the gene expression of myelin basic protein in spinal cord of diabetic rats. J. Mol. Neurosci., 2010, vol. 42, no. 2, pp. 135–139.

24. Nechunaeva E.V. Immuno-biochemical parameters in the early diagnosis of chronic cerebral ischemia. Author. dis. Cand. med. sci. Ekaterinburg, 2010. 25 p. (in Russian).

25. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Report of WHO/IDF Consultation, 2006.

26. ISPAD Clinical Practice Consensus guidelines. 2009.

27. Dedov I.I., Shestakova M.V. Algorithms specialized medical care for patients with diabetes. 6th ed. Moscow, Ministerstvo zdravoohranenija Rossijskoj Federacii; Rossijskaja associacija jendokrinologov; FGBU Jendokrinologicheskij nauchnyj centr Publ., 2013. 120 p. (in Russian).

28. http://www.mocatest.org/default.asp (Acessed: 10 December 2013).

29. Glants S. Biomedical statistics. Moscow, Praktika Publ., 1998. 459 p. (in Russian).

30. Gubler Ye.V., Genkin A.A. Application of nonparametric statistics in biomedical research. Leningrad, Medcine Publ., 1973. 144 p. (in Russian).

31. Fletcher R., Fletcher S., Vagner E. Clinical epidemiology: evidence-based medicine. Moscow, Media Sfera Publ., 1998. 352 p. (in Russian).

32. Strachan M.W., Abraha H.D., Sherwood R.A., Lammie G.A., Deary I.J., Ewing F.M., Perros P., Frier B.M. Evaluation of serum markers of neuronal damage following severe hypoglycaemia in adults with insulin-treated diabetes mellitus. Diabetes Metab. Res. Rev., 1999, vol. 15, no. 1, pp. 5–12.

33. Coleman E., Judd R., Hoe L., Dennis J., Posner P. Effects of diabetes mellitus on astrocyte GFAP and glutamate transporters in the CNS. Glia, 2004, vol. 48, no. 2, pp. 166–178.